- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
RCCA | Association Partnerships
Latest from RCCA
Recent Approvals Show Shift in SOC for Graft-Versus-Host Disease
February 28, 2022
Article
The treatment and preventive agent landscape for graft-versus-host disease is growing for patients with hematologic malignancies who receive a stem cell transplant.
CAR T-Cell Agents for MCL and Indolent Lymphoma
February 25, 2022
Video
Lori A. Leslie, MD, discusses her recent presentation around chimeric antigen receptor T-cell therapy for mantle cell lymphoma and indolent lymphomas.
Patient With Newly Diagnosed Multiple Myeloma Eligible for Multiple Triplet and Quadruplet Regimens
August 13, 2021
Article
During a Targeted Oncology Case-Based Roundtable event, Noa Biran, MD, discussed the case of a 51-year-old man with newly-diagnosed multiple myeloma.
Harper Analyzes Data for Therapies in RET-Mutated NSCLC
August 05, 2021
Article
During a Targeted Oncology Case-Based Roundtable event, Harry Harper, MD, discussed treatment approaches for a 68-year-old patient with RET-mutated non–small cell lung cancer.